Cochlear (ASX:COH) sold more implants in FY26 while gross Margin fell from 74% to 71%. Its Nucleus Nexa system gained developed-market uptake, but management expects FY27 gross margin to remain around 70% to 71%; its 18% medium-term objective concerns net profit margin.

The Global Leader in Cochlear Implants

Cochlear is the world's largest manufacturer of cochlear implants, devices that restore hearing for people with severe to profound hearing loss by directly stimulating the auditory nerve, bypassing damaged parts of the ear that conventional hearing aids cannot help. The company's FY26 results showed sales Revenue of $2.343 billion, up 2 per cent in constant currency terms, with underlying net profit of $322 million landing at the upper end of guidance revised earlier in the year.

Volume Growth Without Matching Revenue Growth

Implant unit volumes rose 5 per cent to 56,692 for the year, yet implant revenue was flat at $1.4 billion in constant currency, a divergence the company attributes to a higher mix of lower-priced units sold into emerging markets. Gross margin fell from 74 per cent to 71 per cent, driven by that unfavourable product mix (a 1.5 percentage point drag), Manufacturing cost variances (1.2 points) and foreign exchange headwinds (0.6 points), with currency alone cutting roughly $24 million from underlying net profit. Net profit margin of 14 per cent remains below the company's 18 per cent medium-term target.

Nexa Adoption and the Margin Outlook

Cochlear’s Nucleus Nexa system accounted for more than 95% of developed-market implant sales by June 2026 and supported an average 3% price increase. The platform underpins longer-term product development, but management did not forecast a near-term return of gross margin to 74% solely from Nexa adoption. It guided FY27 gross margin to approximately 70% to 71%.

What the Evidence Means for a Mature MedTech Leader

A greater proportion of lower-priced units, manufacturing variances and foreign exchange affected FY26 gross margin. Nexa uptake is one Factor in the product mix, while referral activity, production, costs and currencies also matter. Cochlear expects net profit margin, a separate measure, to return to 18% over the medium term.

Risks and Milestones Ahead

Risks include continued currency Volatility given Cochlear's global revenue base, the pace at which emerging-market growth continues to outstrip developed-market Volume (which would keep pressuring blended margin), and execution risk in bringing next-generation features such as drug-eluting electrodes through regulatory approval. Competitive pressure from other cochlear implant and hearing-technology manufacturers also remains a constant, particularly in price-sensitive emerging markets where Cochlear's mix headwind originates.

Cochlear guided FY27 gross margin to approximately 70% to 71% and underlying net profit to A$330 million to A$350 million. The separate 18% net profit margin objective is a medium-term target.